164 related articles for article (PubMed ID: 17623804)
21. Histomathematical analysis of clinical specimens: challenges and progress.
Gannot G; Gillespie JW; Chuaqui RF; Tangrea MA; Linehan WM; Emmert-Buck MR
J Histochem Cytochem; 2005 Feb; 53(2):177-85. PubMed ID: 15684330
[TBL] [Abstract][Full Text] [Related]
22. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.
Zhang Q; Helfand BT; Jang TL; Zhu LJ; Chen L; Yang XJ; Kozlowski J; Smith N; Kundu SD; Yang G; Raji AA; Javonovic B; Pins M; Lindholm P; Guo Y; Catalona WJ; Lee C
Clin Cancer Res; 2009 May; 15(10):3557-67. PubMed ID: 19447876
[TBL] [Abstract][Full Text] [Related]
23. Analysis of prostate cancer by proteomics using tissue specimens.
Liu AY; Zhang H; Sorensen CM; Diamond DL
J Urol; 2005 Jan; 173(1):73-8. PubMed ID: 15592032
[TBL] [Abstract][Full Text] [Related]
24. pS2 (TFF1) expression in prostate carcinoma: correlation with steroid receptor status.
Abdou AG; Aiad HA; Sultan SM
APMIS; 2008 Nov; 116(11):961-71. PubMed ID: 19132993
[TBL] [Abstract][Full Text] [Related]
25. Reduced axin protein expression is associated with a poor prognosis in patients with squamous cell carcinoma of esophagus.
Li AF; Hsu PK; Tzao C; Wang YC; Hung IC; Huang MH; Hsu HS
Ann Surg Oncol; 2009 Sep; 16(9):2486-93. PubMed ID: 19582507
[TBL] [Abstract][Full Text] [Related]
26. Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis.
Becker KF; Schott C; Hipp S; Metzger V; Porschewski P; Beck R; Nährig J; Becker I; Höfler H
J Pathol; 2007 Feb; 211(3):370-8. PubMed ID: 17133373
[TBL] [Abstract][Full Text] [Related]
27. Udp-glucose dehydrogenase as a novel field-specific candidate biomarker of prostate cancer.
Huang D; Casale GP; Tian J; Lele SM; Pisarev VM; Simpson MA; Hemstreet GP
Int J Cancer; 2010 Jan; 126(2):315-27. PubMed ID: 19676054
[TBL] [Abstract][Full Text] [Related]
28. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study.
Michalakis K; Williams CJ; Mitsiades N; Blakeman J; Balafouta-Tselenis S; Giannopoulos A; Mantzoros CS
Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):308-13. PubMed ID: 17301264
[TBL] [Abstract][Full Text] [Related]
29. The role of tissue microarrays in prostate cancer biomarker discovery.
Datta MW; True LD; Nelson PS; Amin MB
Adv Anat Pathol; 2007 Nov; 14(6):408-18. PubMed ID: 18049130
[TBL] [Abstract][Full Text] [Related]
30. Decreased immunostaining for macrophage scavenger receptor is associated with poor prognosis of prostate cancer.
Takayama H; Nonomura N; Nishimura K; Oka D; Shiba M; Nakai Y; Nakayama M; Tsujimura A; Aozasa K; Okuyama A
BJU Int; 2009 Feb; 103(4):470-4. PubMed ID: 18778349
[TBL] [Abstract][Full Text] [Related]
31. Evidence of a novel biomarker, alphas1-Casein, a milk protein, in benign prostate hyperplasia.
Xu K; Ling MT; Wang X; Wong YC
Prostate Cancer Prostatic Dis; 2006; 9(3):293-7. PubMed ID: 16683014
[TBL] [Abstract][Full Text] [Related]
32. Expression of the tumor marker D-galactose-beta-[1-->3]-N-acetyl-D-galactosamine by premalignant and malignant prostate.
Shamsuddin AM; Beasley WM
Arch Pathol Lab Med; 1994 Jan; 118(1):48-51. PubMed ID: 7506904
[TBL] [Abstract][Full Text] [Related]
33. Formalin fixation and immunoreactivity in prostate cancer and benign prostatic tissues.
Jaraj SJ; Egevad L
APMIS; 2010 May; 118(5):383-8. PubMed ID: 20477814
[TBL] [Abstract][Full Text] [Related]
34. The intratumoral distribution of nuclear beta-catenin is a prognostic marker in colon cancer.
Horst D; Reu S; Kriegl L; Engel J; Kirchner T; Jung A
Cancer; 2009 May; 115(10):2063-70. PubMed ID: 19298008
[TBL] [Abstract][Full Text] [Related]
35. Direct cancer tissue proteomics: a method to identify candidate cancer biomarkers from formalin-fixed paraffin-embedded archival tissues.
Hwang SI; Thumar J; Lundgren DH; Rezaul K; Mayya V; Wu L; Eng J; Wright ME; Han DK
Oncogene; 2007 Jan; 26(1):65-76. PubMed ID: 16799640
[TBL] [Abstract][Full Text] [Related]
36. The expression of pluripotency marker Oct 3/4 in prostate cancer and benign prostate hyperplasia.
Monsef N; Soller M; Isaksson M; Abrahamsson PA; Panagopoulos I
Prostate; 2009 Jun; 69(9):909-16. PubMed ID: 19274762
[TBL] [Abstract][Full Text] [Related]
37. Loss of E-cadherin and cytoplasmic-nuclear expression of beta-catenin are the most useful immunoprofiles in the diagnosis of solid-pseudopapillary neoplasm of the pancreas.
Kim MJ; Jang SJ; Yu E
Hum Pathol; 2008 Feb; 39(2):251-8. PubMed ID: 17959228
[TBL] [Abstract][Full Text] [Related]
38. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
Zhigang Z; Wenlu S
Prostate; 2008 Feb; 68(2):190-9. PubMed ID: 18076024
[TBL] [Abstract][Full Text] [Related]
39. Immunoreactivity of ubiquitin in human prostate gland.
Bataineh ZM; Habbal O
Neuro Endocrinol Lett; 2006 Aug; 27(4):517-22. PubMed ID: 16892003
[TBL] [Abstract][Full Text] [Related]
40. EXpression of ErbB proteins in human prostate.
Nasu K; Tanji N; Nishioka R; Wang J; Yanagihara Y; Ozawa A; Yokoyama M; Sakayama K
Arch Androl; 2006; 52(3):185-90. PubMed ID: 16574600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
